1. Introduction {#sec1}
===============

The peroxisome proliferator-activated receptor *γ* (PPAR*γ*)-coactivator *α* (PGC1*α*) has been characterized as a master switch of energy homeostasis \[[@B1]\]. PGC1*α* interacts with transcription factors such as PPAR*γ*, which is a downstream target of PGC1*α*, thereby mediating adaptive thermogenesis, mitochondrial biogenesis, and fiber type switching of the skeletal muscle \[[@B1]\]. Gain-of-function studies indicate an increased resistance to induced fatigue in isolated skeletal muscle of transgenic mice overexpressing PGC1*α* \[[@B2]\]. An activation of PGC1*α* is associated with an increased expression of slow-twitch (type I) fibers which are characterized by an increased mitochondrial biogenesis and thus oxidative metabolism as main energy source \[[@B1]\]. Physical exercise may activate PGC1*α* \[[@B3]\], whereas aging is accompanied by a significant decrease of PGC1*α* expression in skeletal muscle \[[@B4]\]. This decrease in PGC1*α* may impair mitochondrial respiratory capacity, thereby increasing the production of reactive oxygen species which in turn results in glutathione (GSH) depletion and oxidative stress. Thus, strategies are warranted that activate PGC1*α* and increase GSH synthesis and its recycling thereby maintaining muscle function and integrity.

*α*-Lipoic acid (LA) is synthesized from octanoic acid in the mitochondria where it serves as a cofactor of mitochondrial *α*-ketoacid dehydrogenase \[[@B5]\].Beside endogenous synthesis LA may also derive from exogenous dietary sources including supplements (reviewed by \[[@B6]\]). As a component of the electron transport chain in the inner mitochondria membrane, coenzyme Q10 also known as ubiquinone is centrally involved in cellular respiration and mitochondrial biogenesis. Furthermore, it is well known for its free radical scavenging properties, which are partly mediated by electron transfer (reviewed by \[[@B7]\]). LA and Q10 may not work in isolation \[[@B8]\] although little is known regarding the potential synergistic activity of LA plus Q10 in terms of muscle cell physiology. Therefore, in this study we investigated the effect of a combined supplementation of LA plus Q10 on PGC1*α* levels, stress response, and glutathione synthesis in cultured myotubes.

2. Materials and Methods {#sec2}
========================

R(+)LA and Q10 were obtained from Sigma-Aldrich Co. (Munich, Germany). LA was dissolved in DMSO (Carl Roth, Karlsruhe, Germany). Q10 stock solutions were prepared as described previously \[[@B9]\]. The stock solutions were stored at −80°C until usage.

2.1. Cell Culture {#sec2.1}
-----------------

C2C12 cells (Institute for Applied Cell Culture, Munich, Germany) were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM) containing 4.5 g/L glucose, 4 mmol/L L-glutamine, 1 mmol/L sodium pyruvate, 10% fetal calf serum (FCS), 100 U/mL penicillin, and 100 *μ*g/mL streptomycin (PAA, Coelbe, Germany). Cells were grown in 5% CO~2~ at 37°C under a humidified atmosphere. Before each treatment, C2C12 cells were differentiated to myotubes via serum starvation applying DMEM supplemented with 2% horse serum (Gibco, Life technologies, Carlsbad, USA) for 48 h--72 h. All cell-culture plasticware was purchased from Sarstedt (Numbrecht, Germany) unless otherwise stated. For all cell culture assays vehicle controls have been performed and did not affect any of the parameters measured.

2.2. Cytotoxicity Measurement {#sec2.2}
-----------------------------

Cytotoxicity was determined via the neutral red assay \[[@B10]\]. The neutral red assay is based on the pH-dependent accumulation of neutral red in the lysosomes of viable cells. C2C12 cells were seeded in 24-well plates (Fisher Scientific, Schwerte, Germany) at a density of 100,000 cells/well, differentiated for 72 h, and treated with 250 *μ*mol/L LA plus 100 *μ*mol/L Q10 for 24 h in serum-containing medium, respectively. The culture medium containing the test substances was replaced with fresh serum-containing medium including 50 *μ*g/mL of neutral red (Carl Roth). After incubation for 3 h, the medium was removed and the cells were extracted using a solution comprising 50 : 49 : 1 (v/v/v) ethanol, water, and glacial acetic acid. The absorbance was measured in a plate reader (Labsystems, Helsinki, Finland) at 540 nm.

2.3. Transient Transfection and PPAR*γ* Luciferase Reporter Gene Assay {#sec2.3}
----------------------------------------------------------------------

C2C12 cells were differentiated in 24-well plates. The cells were transiently transfected with three vectors: one vector containing the PPAR*γ*-LBD (ligand-binding domain), one UAS-GAL4-vector containing the reporter gene firefly luciferase, and a normalization vector (pRL-TK; Promega, Mannheim, Germany) containing the *Renilla reniformis* luciferase gene. Transfection was performed using JetPei transfection reagent (Polyplus transfection, Illkirch Cedex, France) according to manufacturer\'s instructions. Following 24 h of transfection the test compounds as well as 1 *μ*M rosiglitazone were applied in serum-containing medium and treated for 24 h. Subsequently, cells were lysed and luciferase activity was measured using the Dual-Luciferase reporter gene assay system (Promega) according to the manufacturer\'s protocol in a Tecan Infinite 200 microplate reader (Tecan Group Ltd., Crailsheim, Germany).

2.4. RNA Isolation and Real-Time PCR {#sec2.4}
------------------------------------

C2C12 cells were precultured in 6-well plates at a density of 300,000 cells/well. Cells were differentiated and subsequently treated with 250 *μ*mol/L LA plus 100 *μ*mol/L Q10 and the respective compounds in coapplication for 16 h.

RNA for real-time PCR was isolated with TRIsure following the manufacturer\'s protocol (Bioline, Luckenwalde, Germany). Primers were designed by primer3 software with the following sequences: PGC1*α* forward: TGCCCAGATCTTCCTGAACT; reverse: TCTGTGAGAACCGCTAGCAA; TFAM forward: TAGGAAAATTGCAGCCCTGT; reverse: GCTGAACGAGGTCTTTTTGG; 18SrRNA forward: CCTGCGGCTTAATTTGACTC; reverse: AACTAAGAACGGCCATGCAC (MWG Biotech, Ebersberg, Germany). Real-time PCR was performed using Sensi-Mix one-step kit (Quantace, Berlin, Germany).

2.5. Agilent Microarray Analysis {#sec2.5}
--------------------------------

Differential gene expression was determined via an Agilent MicroArray platform (Source BioScience, ImaGenes GmbH, Berlin, Germany). C2C12 cells were treated as described above. RNA for gene chip analysis was isolated using a Qiagen RNeasy Kit (Duesseldorf, Germany) according to the manufacturer\'s protocol. Agilent Quick Amp Labeling Kit One Color (Agilent Technologies, Santa Clara, USA) was used according to the manufacturer\'s instructions for generation and amplification of fluorescent cRNA. Yield and labeling of cRNA was controlled via NanoDrop measurement (Thermo Fisher Scientific). For hybridization, the Agilent gene expression hybridization kit was used according to the manufacturer\'s protocol. The microarray slides were washed (following the Agilent protocol) and subsequently scanned using an Agilent microarray scanner. Data were extracted using the Agilent Feature Extraction. Quality parameters (e.g., background detrend or grid) and abnormalities of each sample were monitored.

For microarray analysis DAVID Bioinformatics Resources 6.7 (Database for Annotation, Visualization an Integrated Discovery \[[@B11]\]; <http://david.abcc.ncifcrf.gov/>) was used. Therefore, gene IDs of the regulated genes (fold change \> 2 or \<−2) were uploaded. For subsequent functional clustering, KEGG (Kyoto Encyclopedia for Genes and Genomes) pathway maps were used.

2.6. In Silico Promoter Analysis {#sec2.6}
--------------------------------

For promoter analysis, sequences of genes differentially regulated by LA plus Q10 treatment were uploaded to MatInspector Software (<http://www.genomatix.de/>) in order to identify putative binding sites for Nrf2.

2.7. Glutathione Measurement {#sec2.7}
----------------------------

C2C12 cells were treated with the test compounds for 24 h as described above. Subsequently, cells were washed and lysed in 10 mmol/L HCl and repeated freeze-thaw cycles. GSH was determined following the microtiter plate assay protocol according to Vandeputte et al. \[[@B12]\]. In brief, cell protein was precipitated by addition of 6.5% sulfosalicylic acid and centrifugation (2000 × g, 15 min). Cell samples were applied on the microtiter plates, mixed with stock buffer and a reagent mix comprising (final reaction concentration) 0.71 mmol/L DTNB and 0.24 mmol/L NADPH. The reaction was initialized by addition of glutathione reductase (1.2 IU/mL, Sigma Aldrich Co.). Kinetic measurement of the chromophore DTNB-GSH at 415 nm was performed in a plate reader (Labsystems, Helsinki, Finland). Total glutathione was determined using a GSH-standard curve (all reagents Carl Roth unless otherwise stated).

2.8. Western Blot Analysis of PGC1*α* and Nrf2 in Nuclear Extracts {#sec2.8}
------------------------------------------------------------------

For PGC1*α* and Nrf2 detection, cells were treated with the test compounds for 6 h. Subsequently, cells were washed with ice-cold PBS, scraped off, centrifuged, and nuclear extracts were subsequently prepared as described by Wagner et al. (2010) \[[@B13]\]. A quantity of 40 *μ*g protein of each sample were mixed with loading buffer, incubated at 95°C for 5 min and separated on a 12% SDS-PAGE. Subsequently, the samples were transferred onto a PVDF (polyvinylidene fluoride) membrane and blocked with 3% (w/v) skim milk dissolved in TBS + 0.05% (v/v) Tween-20 (TBST) for at least 2 h and probed with antibodies against PGC1 (1 : 200; Santa Cruz Biotechnology Inc., Santa Cruz, USA), Nrf2 (1 : 200; Santa Cruz), TATA box binding protein (TBP; Santa Cruz; 1 : 200), or *α*-tubulin (Abcam, Cambridge, UK; 1 : 5000) at 4°C overnight. Following, the membranes were incubated with a secondary antibody (1 : 4000 anti-rabbit (Bio-Rad, Munich, Germany): Nrf2; 1 : 4000 anti-mouse (Bio-Rad): TBP, *α*-tubulin; 1 : 3000 anti-goat (Santa Cruz): PGC1) for 1 h, and the bands were visualized by using ECL reagent (Thermo Scientific) in a ChemiDoc XRS system (BioRad). Molecular weight of the protein bands was estimated using a Western C protein standard (Bio-Rad).

2.9. Statistical Analysis {#sec2.9}
-------------------------

Statistical analysis was conducted using SPSS 19 (IBM, Chicago, USA). Data were analysed for normality of distribution (Kolmogorov-Smirnov). In case of not normally distributed data the nonparametric Mann-Whitney *U* test was applied. Student\'s *t*-test or one-way analysis of variance (ANOVA) with a Dunnett-T (homogeneous variances) post hoc test was performed. Data are expressed as mean ± SEM. Significance was accepted at *P* \< 0.05.

3. Results {#sec3}
==========

In order to test for cytotoxicity of the test compounds C2C12 myotubes were incubated with 250 *μ*mol/L LA plus 100 *μ*mol/L Q10 (in the following abbreviated as LA plus Q10) for 24 h. Under the conditions investigated cell viability was not negatively affected by the LA plus Q10 treatment ([Figure 1(a)](#fig1){ref-type="fig"}).

PGC1*α* is an important regulator of skeletal muscle energy homoeostasis. Therefore, we determined PGC1*α* nuclear protein levels following 6 h of incubation with LA plus Q10. LA plus Q10 supplementation of C2C12 myotubes significantly enhanced nuclear PGC1*α* protein levels as summarized in [Figure 1(b)](#fig1){ref-type="fig"}. Differences in PGC1*α* protein levels in response to the LA plus Q10 treatment were also reflected in terms of PGC1*α* gene expression ([Figure 1(c)](#fig1){ref-type="fig"}). In fact we found a 70% increase in PGC1*α* mRNA levels in LA-plus-Q10-treated myotubes as compared to untreated control cells.

PGC1*α* is centrally involved in the regulation of PPAR*γ* activity, which is a downstream target of PGC1*α*. Therefore, we determined PPAR*γ* transactivation in transiently transfected C2C12 myotubes using a luciferase reporter gene assay. Rosiglitazone (1 *μ*mol/L; rosi) was used as positive control. Treatment of our C2C12 myotubes with LA plus Q10 significantly increased PPAR*γ* transactivation by approximately 50% ([Figure 1(d)](#fig1){ref-type="fig"}). However, LA plus Q10 cotreatment was less potent than rosiglitazone as far as the induction of PPAR*γ* transactivation is concerned.

Aerobic muscle turnover may be accompanied by induction of reactive oxygen species which are partly produced in the respiratory chain of the inner mitochondrial membrane. Therefore, we investigated if and to what extent the application of LA plus Q10 may affect cellular GSH which is an important endogenous antioxidant. By using Agilent gene chip technology we found several transcripts to be differentially regulated by LA plus Q10 in our C2C12 myotubes. We filtered those genes in terms of their role in GSH synthesis, metabolism, and recycling. Interestingly within the GSH pathway 12 genes were differentially regulated (*P* value \< 0.001, Benjamini enrichment score \< 0.05) due to the LA plus Q10 supplementation as summarized in Figures [2(a)](#fig2){ref-type="fig"} and [2(b)](#fig2){ref-type="fig"}.

Both *γ*GCS light and heavy chain were manifold upregulated by the LA plus Q10 treatment. Since *γ*GCS is the key enzyme in GSH synthesis we further determined cellular GSH levels in our skeletal muscle cells. Importantly, the induction of *γ*GCS gene expression was accompanied by a 4-fold increase in cellular GSH in the LA-plus-Q10-treated cells as compared to control ([Figure 2(c)](#fig2){ref-type="fig"}).

Glutathione reductase (GSR) is centrally involved in the NADPH-mediated reduction of GSSG to GSH, thereby providing GSH for further reactions. Following incubation with LA plus Q10, we observed a 3.2-fold increase in GSR gene expression ([Figure 2(c)](#fig2){ref-type="fig"}). Interestingly, not only GSR but also glucose-6-phosphate dehydrogenase 2 (G6PD) and phosphogluconate dehydrogenase (PGD) gene expression was induced by LA plus Q10. Both enzymes provide NADPH which is used by GSR for GSSG reduction.

Induction of glutathione-S-transferase (GST) may protect the skeletal muscle from lipid peroxides thereby improving stress response. In fact, it has been shown that GST inactivates lipid peroxides such as 4-hydroxynonenal due to conjugation with GSH \[[@B14]\]. We found in our myotubes various genes encoding GST (GST *α*1, GST *α*2, GST *α*3, GST *α*4, GST *π*1, GST *π*2, GST *μ*6) to be upregulated by the cotreatment of LA plus Q10 (Figures [2(a)](#fig2){ref-type="fig"} and [2(b)](#fig2){ref-type="fig"}).

To identify binding sites for Nrf2 in murine promoter regions in LA-plus-Q10-regulated genes, the respective murine promoter sequences were uploaded to MatInspector. As summarized in [Figure 2(b)](#fig2){ref-type="fig"}, several binding sites for Nrf2 have been identified in the promoter of the *γ*GCS (GCLC (0--4 putative binding sites), GCLM (0--4)), GSR (1--5), GST (GST *α*1 (1-2), GST *α*2 (1), GST *α*3 (0--2), GST *α*4 (0/4), GST *π*1 (0--8), GST *π*2 (0--8), GST *μ*6 (0--2)) ODC1 (1), G6PD (1), and PGD (1--6) genes, respectively, ([Figure 2(b)](#fig2){ref-type="fig"}).

Treatment of C2C12 cells with LA plus Q10 increased TFAM mRNA levels by 70% (*P* = 0.078) as compared to controls ([Figure 3(a)](#fig3){ref-type="fig"}). Furthermore, LA plus Q10 supplementation resulted in an increase in nuclear Nrf2 levels as summarized in [Figure 3(b)](#fig3){ref-type="fig"}.

4. Discussion {#sec4}
=============

Under the conditions investigated LA plus Q10 significantly increased nuclear PGC1*α* levels in our C2C12 skeletal muscle cells. PGC1*α* partly controls PPAR*γ* activation which is centrally involved in cellular glucose uptake. In fact it has been previously shown that lipoic acid may stimulate glucose uptake and insulin sensitivity in adipocytes via a PPAR*γ*-dependent signal transduction pathway \[[@B15], [@B16]\].

PGC1*α* is a key factor in mitochondrial biogenesis. PGC1*α*, in the presence of the nuclear respiratory factor 1 (NRF1), coactivates the mitochondrial transcription factor A (TFAM; also called mtTFA) which is essential for mitochondrial replication and transcription \[[@B17], [@B18]\]. Therefore, we determined TFAM levels in our LA-plus-Q10-treated myotubes. Interestingly, LA plus Q10 resulted in an increase in TFAM mRNA levels as compared to untreated controls ([Figure 3(a)](#fig3){ref-type="fig"}). LA plus Q10 cotreatment was more potent than the single treatment with LA and Q10 per se in increasing TFAM gene expression (data not shown). Further studies are needed to prove whether the increase in TFAM gene expression due to the LA plus Q10 cotreatment is also reflected in terms of increased nuclear TFAM protein levels as well as an increased cellular mitochondrial density, ATP synthesis, and oxygen consumption.

We observed a significant increase in cellular GSH levels in response to LA plus Q10 treatment in our skeletal muscle cells. Similar to PGC1*α* cellular GSH levels decrease with age \[[@B19]\]. Thus, LA plus Q10 may prevent age-dependent GSH depletion. The underlying mechanisms by which LA plus Q10 increased cellular GSH may be partly related to an increased cysteine uptake as previously reported \[[@B20]\]. Furthermore, in the present study LA plus Q10 significantly increased gene expression of *γ*GCS, the rate limiting enzyme of GSH synthesis. *γ*GCS gene expression is under transcriptional control of nuclear factor erythroid-like 2 derived factor 2 (Nrf2), a Cap N\'Collar basic leucine zipper transcription factor \[[@B21]--[@B23]\]. Interestingly, LA plus Q10 treatment also manifold upregulated numerous GSTs which are also Nrf2 target genes \[[@B24]\]. Therefore, we determined Nrf2 nuclear levels in our skeletal muscle cells in response to the LA plus Q10 treatment. Since LA plus Q10 treatment substantially increased nuclear Nrf2 levels, it seems plausible that the induction of GSH via *γ*GCS as well as the induction of GST gene expression in our C2C12 cells may have occurred via a Nrf2-dependent mechanism. In fact, it has been recently suggested that LA, may act as an electrophile which targets cysteine residues of the Nrf2 inhibitor Keap1 \[[@B25]\].

Our gene expression analysis also reveals ornithine decarboxylase 1 (ODC1) as a LA plus Q10 sensitive molecular target (fold change = 2.1, see [Figure 2(b)](#fig2){ref-type="fig"}). Interestingly, ODC1 is induced by exercise in skeletal muscle \[[@B26]\]. The increase in ODC1 activity may in turn increase cellular levels of putrescine, spermine, and spermidine \[[@B27]\], thereby improving DNA stability \[[@B28]\], which warrants further investigations.

In this study we tested the combination of LA plus Q10 in terms of PGC1*α* activity, stress response, and cellular GSH levels. However, we conducted also experiments using LA and Q10 as single treatments in order to relate our results to any of the test substances administered (data not shown). While Q10 was mainly mediating PGC1*α* inducing activity, LA increased stress response and cellular GSH levels. As far as TFAM gene expression is concerned, neither of the single test compounds enhanced TFAM. Thus, TFAM induction may be due to synergistic interaction between LA and Q10 in coapplication. Accordingly, in order to simultaneously induce PGC1, stress response genes, and cellular GSH levels in skeletal muscle cells a combination of LA plus Q10 rather than a treatment with the single compound may be suggested.

Overall present data indicate that a combination of lipoic acid plus coenzyme Q10 induces PGC1*α*, improves stress response, and increases cellular glutathione levels in cultured C2C12 skeletal muscle cells as summarized in [Figure 4](#fig4){ref-type="fig"}. We supplemented our myotubes with 250 *μ*mol/L LA and 100 *μ*mol/L Q10. LA concentrations, as used in this study, are by in large physiologically achievable \[[@B6], [@B29]\], whereas Q10 levels seem to be higher than those achievable in human plasma and skeletal muscle \[[@B30]\]. Thus, current finding regarding the role of LA and Q10 in terms of PGC1*α* activity, stress response, and antioxidant defense in cultured skeletal muscle cells in vitro should be verified in appropriate in vivo models.
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![(a) Viability of differentiated C2C12 cells following incubation with 250 *μ*mol/L LA plus 100 *μ*mol/L Q10 for 24 h (data are mean + SEM). (b) PGC1 induction in C2C12 cells following incubation with 250 *μ*mol/L LA plus 100 *μ*mol/L Q10 for 6 h in nuclear cell lysates and (c) PGC1*α* mRNA levels in response to the LA plus Q10 treatment (data are mean + SEM of three independent experiments; \*indicates significant difference to the control cells; *P* \< 0.05; Student\'s *t*-test). (d) The increase in PGC1*α* is accompanied by an increased PPAR*γ* transactivation as shown in transiently transfected C2C12 cells (data are mean + SEM of two independent experiments; \*indicates significant difference to the control cells; *P* \< 0.05; one-way ANOVA).](OXIMED2012-835970.001){#fig1}

![(a) Treatment of C2C12 cells with 250 *μ*mol/L LA plus 100 *μ*mol/L Q10 for 16 h differentially affects genes encoding proteins involved in glutathione synthesis, recycling, and metabolism as well as glutathione-related phase II response genes including *γ*-glutamylcysteine-synthetase (*γ*GCS), glutathione reductase (GSR), glucose-6-phosphate dehydrogenase (G6PD), phosphogluconate dehydrogenase (PGD), and glutathione-S-transferases (GST), according to DAVID and KEGG pathway analysis. (b) Indicates fold changes, gene IDs, and the respective putative Nrf2 binding sites in the alternative murine promoter sequences of LA-plus-Q10-regulated genes as determined via MatInspector. (c) Glutathione (GSH) concentration in C2C12 cells in response to LA plus Q10 treatment (data are mean + SEM of three independent experiments; \*indicates significant difference to the control cells; *P* \< 0.05; Student\'s *t*-test).](OXIMED2012-835970.002){#fig2}

![(a) TFAM mRNA and (b) nucleic Nrf2 protein levels of C2C12 cells following incubation with 250 *μ*mol/L LA plus 100 *μ*mol/L Q10 for 16 h (mRNA data are mean + SEM of three independent experiments; Mann-Whitney *U* test).](OXIMED2012-835970.003){#fig3}

![Molecular mechanisms by which the coadministration of LA plus Q10 may improve skeletal muscle energy metabolism and integrity. LA plus Q10 induce the transcription factor PGC1*α* which may activate TFAM. Furthermore, LA plus Q10 induce GSTs and genes encoding enzymes involved in GSH synthesis and recycling. Ultimately, LA plus Q10 may increase mitochondrial biogenesis, improve stress response, and increase cellular GSH levels.](OXIMED2012-835970.004){#fig4}
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